Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA radioligands are a class of targeted radiopharmaceuticals designed to bind to prostate-specific membrane antigen (PSMA), a cell-surface protein highly overexpressed in prostate cancer cells, particularly in metastatic and castration-resistant stages. These agents typically consist of a PSMA-targeting moiety (such as a small-molecule peptidomimetic, peptide, or monoclonal antibody) conjugated via a linker to a chelator holding a radioactive isotope. In theranostics, diagnostic PSMA radioligands (labeled with positron emitters like gallium-68 or fluorine-18) are used for PET imaging to select patients, while therapeutic PSMA radioligands (labeled with beta-emitters like lutetium-177 or alpha-emitters like actinium-225) deliver localized, cytotoxic radiation directly to the tumor site, causing DNA double-strand breaks and subsequent cell death. The class is led by approved therapeutics such as lutetium Lu 177 vipivotide tetraxetan (Pluvicto), which has established survival benefits across metastatic prostate cancer indications.
| Indication | Highest phase | Status |
|---|---|---|
| metastatic castration-resistant prostate cancer (mCRPC) | Preclinical | Active |
| metastatic castration-sensitive prostate cancer (mCSPC) / metastatic hormone-sensitive prostate cancer (mHSPC) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
1 clinical trial with PSMA radioligand
Trial-by-trial design, status and readouts are in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PSMA radioligand.
Work on PSMA radioligand? Claim this page to correct or add information. Claim this page